(Q37942777)

25 August 2017

1 reference

title

Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy (English)

1 reference

25 August 2017

1 reference

1 reference

Choongho Lee

1

1 reference

25 August 2017

publication date

1 September 2011

1 reference

Archives of Pharmacal Research

25 August 2017

published in

1 reference

25 August 2017

volume

34

1 reference

25 August 2017

issue

9

1 reference

25 August 2017

page(s)

1403-1407

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Protease and polymerase inhibitors for the treatment of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Efficient initiation of HCV RNA replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

A second hepatitis C virus-encoded proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

The hepatitis C virus NS5A inhibitor (BMS-790052) alters the subcellular localization of the NS5A non-structural viral protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Identification of Hepatitis C Virus NS5A Inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Continuous human cell lines inducibly expressing hepatitis C virus structural and nonstructural proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Replication of hepatitis C virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Reduction of hepatitis C virus NS5A hyperphosphorylation by selective inhibition of cellular kinases activates viral RNA replication in cell culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Global epidemiology of hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Small molecules targeting hepatitis C virus-encoded NS5A cause subcellular redistribution of their target: insights into compound modes of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

Peginterferon alfa-2a in patients with chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12272-011-0921-6

10.1007/S12272-011-0921-6

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference